结直肠癌(CRC)仍然是全球主要的健康问题。需要深入探索其进展和潜在治疗干预的复杂分子机制。转化生长因子-β(TGF-β)信号,与CRC相关的关键通路在早期阶段作为肿瘤抑制因子和在晚期阶段作为肿瘤进展的启动子发挥双重作用。最近的研究揭示了非编码RNA(ncRNA)在调节TGF-β信号通路中的关键参与,为我们对CRC发病机制的理解带来了新的复杂性。这篇全面的综述综合了关于各类ncRNAs的功能和治疗潜力的知识现状。包括microRNAs(miRNAs),长链非编码RNA(lncRNA),和环状RNAs(circRNAs),在CRC中TGF-β信号传导的背景下。这些ncRNAs和TGF-β途径的关键成分之间复杂的相互作用被解剖,揭示了有助于肿瘤抑制和促进之间动态平衡的调控网络。重点放在特定ncRNAs的失调如何破坏这种微妙的平衡,促进儿童权利委员会的启动,programming,和转移。此外,该综述对针对CRC中与TGF-β信号相关的ncRNAs的新兴治疗策略进行了批判性评估。讨论了这些ncRNAs作为诊断和预后生物标志物的潜力,强调它们的临床相关性。此外,开发基于RNA的疗法的挑战和前景,如RNA干扰和基于CRISPR/Cas的方法,在调节TGF-β信号传导用于CRC治疗的背景下进行了探索。总之,这篇综述全面概述了ncRNAs与CRC中TGF-β信号通路之间的复杂相互作用。通过解开这些调控元件的功能意义,我们获得了对CRC分子景观的宝贵见解,为开发旨在通过操纵ncRNAs调节TGF-β信号级联的新型靶向治疗干预措施铺平了道路。
Colorectal cancer (CRC) remains a major global health concern, necessitating an in-depth exploration of the intricate molecular mechanisms underlying its progression and potential therapeutic interventions. Transforming Growth Factor-β (TGF-β) signaling, a pivotal pathway implicated in CRC plays a dual role as a tumor suppressor in the early stages and a promoter of tumor progression in later stages. Recent research has shed light on the critical involvement of noncoding RNAs (ncRNAs) in modulating the TGF-β signaling pathway, introducing a new layer of complexity to our understanding of CRC pathogenesis. This comprehensive
review synthesizes the current state of knowledge regarding the function and therapeutic potential of various classes of ncRNAs, including microRNAs (miRNAs), long noncoding RNAs (lncRNAs), and circular RNAs (circRNAs), in the context of TGF-β signaling in CRC. The intricate interplay between these ncRNAs and key components of the TGF-β pathway is dissected, revealing regulatory networks that contribute to the dynamic balance between tumor suppression and promotion. Emphasis is placed on how dysregulation of specific ncRNAs can disrupt this delicate equilibrium, fostering CRC initiation, progression, and metastasis. Moreover, the
review provides a critical appraisal of the emerging therapeutic strategies targeting ncRNAs associated with TGF-β signaling in CRC. The potential of these ncRNAs as diagnostic and prognostic biomarkers is discussed, highlighting their clinical relevance. Additionally, the challenges and prospects of developing RNA-based therapeutics, such as RNA interference and CRISPR/Cas-based approaches, are explored in the context of modulating TGF-β signaling for CRC treatment. In conclusion, this
review offers a comprehensive overview of the intricate interplay between ncRNAs and the TGF-β signaling pathway in CRC. By unraveling the functional significance of these regulatory elements, we gain valuable insights into the molecular landscape of CRC, paving the way for the development of novel and targeted therapeutic interventions aimed at modulating the TGF-β signaling cascade through the manipulation of ncRNAs.